Published in Cancer Res on September 29, 2009
A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat Struct Mol Biol (2011) 3.10
mTOR inhibition prevents epithelial stem cell senescence and protects from radiation-induced mucositis. Cell Stem Cell (2012) 1.99
Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Ther (2011) 1.66
Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. Clin Cancer Res (2011) 1.35
Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol (2012) 1.33
The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses. Neoplasia (2012) 1.28
RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas. Cancer Discov (2013) 1.25
Strategies for optimizing the response of cancer and normal tissues to radiation. Nat Rev Drug Discov (2013) 1.25
The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo. PLoS One (2011) 1.19
The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer. PLoS One (2011) 1.19
mTOR pathway in colorectal cancer: an update. Oncotarget (2014) 1.15
PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes. Acta Pharmacol Sin (2012) 1.15
Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy. Cancer Biol Ther (2011) 1.14
A selective inhibitor reveals PI3Kγ dependence of T(H)17 cell differentiation. Nat Chem Biol (2012) 1.13
Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells. PLoS One (2012) 1.12
Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. PLoS One (2012) 1.11
NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity. Radiat Oncol (2012) 1.11
Identification of novel candidate compounds targeting TrkB to induce apoptosis in neuroblastoma. Cancer Med (2014) 1.10
Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clin Cancer Res (2010) 1.07
Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma. Clin Cancer Res (2013) 1.07
Microenvironment and radiation therapy. Biomed Res Int (2012) 1.06
Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer. Oncotarget (2013) 1.05
Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Mol Pharmacol (2012) 1.04
Novel small-molecule inhibitors of Bcl-XL to treat lung cancer. Cancer Res (2013) 0.99
Novel PI3K and mTOR Inhibitor NVP-BEZ235 Radiosensitizes Breast Cancer Cell Lines under Normoxic and Hypoxic Conditions. Breast Cancer (Auckl) (2014) 0.98
Improving the efficacy of chemoradiation with targeted agents. Cancer Discov (2014) 0.97
Radiosensitization of Glioblastoma Cell Lines by the Dual PI3K and mTOR Inhibitor NVP-BEZ235 Depends on Drug-Irradiation Schedule. Transl Oncol (2013) 0.96
Sequential dosing in chemosensitization: targeting the PI3K/Akt/mTOR pathway in neuroblastoma. PLoS One (2013) 0.94
NVP-BEZ-235 enhances radiosensitization via blockade of the PI3K/mTOR pathway in cisplatin-resistant non-small cell lung carcinoma. Genes Cancer (2014) 0.93
Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel) (2015) 0.93
NVP-BEZ235, a novel dual PI3K/mTOR inhibitor, enhances the radiosensitivity of human glioma stem cells in vitro. Acta Pharmacol Sin (2013) 0.89
DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of Cancer. Biomolecules (2015) 0.88
Targeting oncogenic KRAS in non-small cell lung cancer cells by phenformin inhibits growth and angiogenesis. Am J Cancer Res (2015) 0.88
Regulation of O2 consumption by the PI3K and mTOR pathways contributes to tumor hypoxia. Radiother Oncol (2014) 0.85
Inhibitors of phosphatidylinositol-3-kinase in cancer therapy. Mol Aspects Med (2010) 0.83
Nullifying the CDKN2AB locus promotes mutant K-ras lung tumorigenesis. Mol Cancer Res (2014) 0.83
Comparative analysis of radiosensitizers for K-RAS mutant rectal cancers. PLoS One (2013) 0.82
The Biological Role of PI3K Pathway in Lung Cancer. Pharmaceuticals (Basel) (2012) 0.81
Fatty Acid Oxidation Mediated by Acyl-CoA Synthetase Long Chain 3 Is Required for Mutant KRAS Lung Tumorigenesis. Cell Rep (2016) 0.80
Chronic modulation of AMP-Kinase, Akt and mTOR pathways by ionizing radiation in human lung cancer xenografts. Radiat Oncol (2012) 0.80
Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821. Bioorg Med Chem Lett (2016) 0.79
Genotype directed therapy in murine mismatch repair deficient tumors. PLoS One (2013) 0.78
PIAS1-FAK Interaction Promotes the Survival and Progression of Non-Small Cell Lung Cancer. Neoplasia (2016) 0.77
Selective targeting of the mTORC1/2 protein kinase complexes leads to antileukemic effects in vitro and in vivo. Blood Cancer J (2011) 0.77
Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations. Clin Cancer Res (2015) 0.77
Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways. Br J Cancer (2016) 0.77
Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer (NSCLC) to cytotoxic therapy: translational biology and rationale for current clinical trials. Oncotarget (2017) 0.76
Adapting a drug screening platform to discover associations of molecular targeted radiosensitizers with genomic biomarkers. Mol Cancer Res (2015) 0.76
Selective tumor killing based on specific DNA-damage response deficiencies. Cancer Biol Ther (2012) 0.76
Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment. Mol Cell Oncol (2014) 0.76
Molecular characterization of pulmonary sarcomatoid carcinoma: analysis of 33 cases. Mod Pathol (2016) 0.75
Role of Akt signaling in resistance to DNA-targeted therapy. World J Clin Oncol (2016) 0.75
Opportunities for Radiosensitization in the Stereotactic Body Radiation Therapy (SBRT) Era. Cancer J (2016) 0.75
Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946). ChemMedChem (2016) 0.75
Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer. Clin Cancer Res (2016) 0.75
Targeting the PI3K/AKT/mTOR signaling pathway as an effectively radiosensitizing strategy for treating human oral squamous cell carcinoma in vitro and in vivo. Oncotarget (2017) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A (2004) 33.85
AKT/PKB signaling: navigating downstream. Cell (2007) 31.26
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet (2006) 17.19
A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods (1991) 16.64
Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer (2003) 15.17
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14.47
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med (2005) 13.40
Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature (2006) 12.13
mTOR and cancer: insights into a complex relationship. Nat Rev Cancer (2006) 11.86
Clonogenic assay of cells in vitro. Nat Protoc (2006) 11.85
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest (2008) 10.74
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther (2008) 10.35
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A (2005) 6.62
Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell (2007) 6.44
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res (2008) 5.82
Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev (2001) 5.67
Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A (2006) 4.84
Cell death by mitotic catastrophe: a molecular definition. Oncogene (2004) 4.75
Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res (2001) 4.73
The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov (2008) 4.03
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res (2008) 3.70
PIK3CA mutations and copy number gains in human lung cancers. Cancer Res (2008) 3.42
PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol Cell (2008) 3.27
NCI-Navy Medical Oncology Branch cell line data base. J Cell Biochem Suppl (1996) 3.24
A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell (2006) 2.95
Palliative thoracic radiotherapy for lung cancer: a systematic review. J Clin Oncol (2008) 2.50
Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res (2008) 2.15
Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras. Cancer Res (2005) 2.01
K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis (1999) 1.67
The Ras radiation resistance pathway. Cancer Res (2001) 1.59
Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol Cancer Ther (2006) 1.53
Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Res (2005) 1.41
Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines. Clin Cancer Res (2008) 1.35
PARP-1 modifies the effectiveness of p53-mediated DNA damage response. Oncogene (2002) 1.33
Potentiation of halogenated pyrimidine radiosensitizers in human carcinoma cells by beta-lapachone (3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran- 5,6-dione), a novel DNA repair inhibitor. Cancer Res (1987) 1.08
Gene mutations in lung cancer: promising predictive factors for the success of molecular therapy. PLoS Med (2005) 0.94
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst (2005) 13.00
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Lung cancer in never smokers--a different disease. Nat Rev Cancer (2007) 6.41
Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res (2004) 5.57
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest (2009) 5.07
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet (2012) 4.70
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One (2009) 4.62
Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res (2005) 4.25
Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Lett (2006) 3.94
Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer (2006) 3.92
Genomic alterations in cultured human embryonic stem cells. Nat Genet (2005) 3.89
Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell (2011) 3.88
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell (2006) 3.73
Identification of a tumour suppressor network opposing nuclear Akt function. Nature (2006) 3.68
Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res (2006) 3.45
PIK3CA mutations and copy number gains in human lung cancers. Cancer Res (2008) 3.42
Focus on lung cancer. Cancer Cell (2002) 3.41
Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res (2006) 3.40
The mechanisms of PML-nuclear body formation. Mol Cell (2006) 3.22
Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res (2006) 3.21
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell (2006) 3.20
Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst (2004) 3.17
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res (2009) 3.13
The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res (2005) 3.11
Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol (2005) 2.95
Retracted Ku70 suppresses the apoptotic translocation of Bax to mitochondria. Nat Cell Biol (2003) 2.83
Expression of nicotinic acetylcholine receptor subunit genes in non-small-cell lung cancer reveals differences between smokers and nonsmokers. Cancer Res (2007) 2.81
Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One (2009) 2.79
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res (2002) 2.71
Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol (2012) 2.56
Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res (2010) 2.54
Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem (2011) 2.46
PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell Biol (2004) 2.45
A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol (2007) 2.43
Presence of simian virus 40 DNA sequences in human lymphomas. Lancet (2002) 2.21
EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res (2005) 2.17
Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis. Proc Natl Acad Sci U S A (2010) 2.16
A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med (2006) 2.16
High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH. Int J Cancer (2006) 2.16
Retracted Aberrant methylation of Reprimo in human malignancies. Int J Cancer (2005) 2.13
Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res (2012) 2.10
Personalized medicine and inhibition of EGFR signaling in lung cancer. N Engl J Med (2009) 2.10
Lung cancer preneoplasia. Annu Rev Pathol (2006) 2.04
Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer (2003) 2.01
Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem (2003) 2.01
Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS One (2009) 1.94
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone. Proc Natl Acad Sci U S A (2007) 1.92
Oxygen concentration determines the biological effects of NOTCH-1 signaling in adenocarcinoma of the lung. Cancer Res (2007) 1.88
The TP53 gene, tobacco exposure, and lung cancer. Hum Mutat (2003) 1.86
RNA interference-mediated knockdown of DNA methyltransferase 1 leads to promoter demethylation and gene re-expression in human lung and breast cancer cells. Cancer Res (2004) 1.84
EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res (2009) 1.79
Methylation and gene silencing of the Ras-related GTPase gene in lung and breast cancers. Ann Surg Oncol (2006) 1.79
Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer (2004) 1.79
Mu-calpain activation in beta-lapachone-mediated apoptosis. Cancer Biol Ther (2003) 1.76
Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res (2002) 1.74
Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. Mol Cancer Ther (2011) 1.74
Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer. Cancer Res (2004) 1.74
Relationships between EGFR signaling-competent and endocytosis-competent membrane microdomains. Mol Biol Cell (2005) 1.67
DNA mismatch repair-dependent response to fluoropyrimidine-generated damage. J Biol Chem (2004) 1.65
cRGD-functionalized polymer micelles for targeted doxorubicin delivery. Angew Chem Int Ed Engl (2004) 1.63
Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell (2013) 1.60
Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations. Mol Cancer Res (2013) 1.57
Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines. J Biol Chem (2002) 1.55
Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Cancer Res (2006) 1.55
Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells. Cancer Res (2013) 1.54
Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers. Cancer Res (2006) 1.53
Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib. Leuk Lymphoma (2009) 1.53
Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med (2007) 1.52
Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation. Oncogene (2003) 1.52
DNA methylation in health, disease, and cancer. Curr Mol Med (2007) 1.52
TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer. J Clin Invest (2009) 1.50
Aberrant methylation of the CDH13 (H-cadherin) promoter region in colorectal cancers and adenomas. Cancer Res (2002) 1.50
A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia. J Natl Cancer Inst (2002) 1.50
MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int J Cancer (2009) 1.48
Knockdown of ZEB1, a master epithelial-to-mesenchymal transition (EMT) gene, suppresses anchorage-independent cell growth of lung cancer cells. Cancer Lett (2010) 1.47
Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events. Genome Res (2012) 1.47
Aberrant promoter methylation of human DAB2 interactive protein (hDAB2IP) gene in lung cancers. Int J Cancer (2005) 1.45
Calcium-dependent modulation of poly(ADP-ribose) polymerase-1 alters cellular metabolism and DNA repair. J Biol Chem (2006) 1.43
Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene (2002) 1.43
TRAF6 is an amplified oncogene bridging the RAS and NF-κB pathways in human lung cancer. J Clin Invest (2011) 1.42
Multifocal lung cancers--clonality vs field cancerization and does it matter? J Natl Cancer Inst (2009) 1.41
Retracted Methylation of apoptosis related genes in the pathogenesis and prognosis of prostate cancer. Cancer Lett (2006) 1.40
Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer. Clin Cancer Res (2004) 1.39
Molecular pathogenesis of lung cancer. Annu Rev Physiol (2002) 1.39
Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res (2002) 1.39
Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers. Int J Cancer (2003) 1.39
Hierarchical clustering of lung cancer cell lines using DNA methylation markers. Cancer Epidemiol Biomarkers Prev (2002) 1.38
Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma. PLoS Med (2010) 1.38
Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res (2004) 1.38
Smoking molecular damage in bronchial epithelium. Oncogene (2002) 1.38
Delayed activation of insulin-like growth factor-1 receptor/Src/MAPK/Egr-1 signaling regulates clusterin expression, a pro-survival factor. J Biol Chem (2005) 1.36
Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer. Cancer (2006) 1.35
Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis. Clin Cancer Res (2011) 1.33
Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int J Cancer (2004) 1.32
In vivo off-resonance saturation magnetic resonance imaging of alphavbeta3-targeted superparamagnetic nanoparticles. Cancer Res (2009) 1.32